![grail cancer detection scientist](https://assets.grail.com/wp-content/uploads/2022/06/grail-cancer-detection.png)
GRAIL at AACR 2024
GRAIL Data
Read our press release to learn what we are presenting at AACR
Click on any of the items below to open the abstract in a new tab.
- Early Real-World Experience with Repeat Multi-Cancer Early Detection (MCED) Testing
- Prognostic Significance of Blood-Based Multi-Cancer Detection in Cell-Free DNA: 4-Year Outcomes Analysis
- Most Cancer Deaths Are Unaddressed by Current Screening Paradigms
- A Targeted Methylation-Based Multi-Cancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer and Minimizes Overdiagnosis
- Identification of Cancer Subtypes With a ctDNA-Based Targeted Methylation Assay
- PATHFINDER 2: A Prospective Study to Evaluate Safety and Performance of a Multi-Cancer Early Detection Test in a Population Setting
Click on any of the items below to open the presentation in a new tab.
- Identification of Cancer Subtypes With a ctDNA-Based Targeted Methylation Assay
- Most Cancer Deaths are Unaddressed by Current Screening Paradigms
- PATHFINDER 2: A Prospective Study to Evaluate Safety and Performance of a Multi-Cancer Early Detection Test in a Population Setting
- Early Real-World Experience With Repeat Multi-Cancer Early Detection (MCED) Testing
- Prognostic Significance of Blood-Based Multi-Cancer Detection in Cell-Free DNA: 4-Year Outcomes Analysis
- A Targeted Methylation-Based MCED Blood Test Preferentially Detects High-Grade Prostate Cancer and Minimizes Overdiagnosis
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.